Pancreatic Cancer Research

ResearcherGuangxi Medical UniversityActive in the last 2 years

Shanyu Qin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3162-3070; OpenAlex author ID A5048552499. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 18)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2017: 3 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 4 papers · 2023: 4 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 22

  1. The effect of HBE1 on resistance to gemcitabine in pancreatic cancer cells. Last author DOI 10.1016/j.ajg.2026.01.006↗
  2. Knockdown of p53 Enhances LncRNA A2M-AS1 Inhibition of Pancreatic Cancer Progression via Regulating MAPK Pathway. Last author DOI 10.1002/cam4.70956↗
  3. An endoscopic ultrasound-based interpretable deep learning model and nomogram for distinguishing pancreatic neuroendocrine tumors from pancreatic cancer. Co-author DOI 10.1038/s41598-024-84749-7↗
  4. EUS-based intratumoral and peritumoral machine learning radiomics analysis for distinguishing pancreatic neuroendocrine tumors from pancreatic cancer. Last author DOI 10.3389/fonc.2025.1442209↗
  5. Bidirectional effects of morphine on pancreatic cancer progression via the p38/JNK pathway. Co-author DOI 10.1038/s41598-024-75089-7↗
  6. EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer. Last author DOI 10.1186/s12885-024-12005-2↗
  7. Construction and validation of an endoscopic ultrasonography-based ultrasomics nomogram for differentiating pancreatic neuroendocrine tumors from pancreatic ca… Last author DOI 10.3389/fonc.2024.1359364↗
  8. Differential Plasma Proteins Identified via iTRAQ-Based Analysis Serve as Diagnostic Markers of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1155/2023/5145152↗
  9. Identification of ZBTB4 as an immunological biomarker that can inhibit the proliferation and invasion of pancreatic cancer. Last author DOI 10.1186/s12885-023-10749-x↗
  10. Local Sustained Chemotherapy of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Injection of Biodegradable Thermo-Sensitive Hydrogel. Last author DOI 10.2147/ijn.s417445↗
  11. Erratum: Local Sustained Chemotherapy of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Injection of Biodegradable Thermo-Sensitive Hydrogel [Corrigendum… Last author DOI 10.2147/ijn.s437867↗
  12. IFN-γ affects pancreatic cancer properties by MACC1-AS1/MACC1 axis via AKT/mTOR signaling pathway. Last author DOI 10.1007/s12094-021-02748-w↗
  13. MACC1 promotes pancreatic cancer metastasis by interacting with the EMT regulator SNAI1. Last author DOI 10.1038/s41419-022-05285-8↗
  14. The effect and mechanism of miR-30e-5p targeting SNAI1 to regulate epithelial-mesenchymal transition on pancreatic cancer. Co-author DOI 10.1080/21655979.2022.2050880↗
  15. LncRNA A2M-AS1 Promotes Ferroptosis in Pancreatic Cancer via Interacting With PCBP3. Last author DOI 10.1158/1541-7786.mcr-22-0024↗
  16. Identification of a Five-Gene Prognostic Signature Related to B Cells Infiltration in Pancreatic Adenocarcinoma. Last author DOI 10.2147/ijgm.s324432↗
  17. Relationship between a 7-mRNA signature of the pancreatic adenocarcinoma microenvironment and patient prognosis (a STROBE-compliant article). Last author DOI 10.1097/md.0000000000021287↗
  18. Identification of Hub Prognosis-Associated Oxidative Stress Genes in Pancreatic Cancer Using Integrated Bioinformatics Analysis. Last author DOI 10.3389/fgene.2020.595361↗
  19. Targeted blockade of interleukin 9 inhibits tumor growth in murine model of pancreatic cancer. Last author DOI 10.17219/acem/104543↗
  20. Identification of novel therapeutic target genes and pathway in pancreatic cancer by integrative analysis. Last author DOI 10.1097/md.0000000000008261↗
  21. Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis. Last author DOI 10.1155/2017/2831056↗
  22. [Interleukin-9 promotes pancreatic cancer cell proliferation and migration via activation of STAT3 pathway]. Co-author PMID 29089082↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haixing Jiang · 16 shared papers, 2017–2026 · strength 3.28
  2. Jing Ning · 4 shared papers, 2023–2024 · strength 0.88
  3. Yi Nan · 3 shared papers, 2025 · strength 0.76
  4. Shuangyang Mo · 3 shared papers, 2024–2025 · strength 0.75
  5. Xianglian Zhang · 4 shared papers, 2020–2025 · strength 0.75
  6. Dan Yang · 3 shared papers, 2023–2024 · strength 0.72
  7. Xiubing Chen · 3 shared papers, 2023–2024 · strength 0.60
  8. Xin Qiu · 3 shared papers, 2020–2022 · strength 0.50
  9. Yu Cen · 2 shared papers, 2022–2025 · strength 0.40
  10. Bang-li Hu · 4 shared papers, 2017–2019 · strength 0.39
  11. Shaomei Tang · 2 shared papers, 2021–2022 · strength 0.38
  12. Jiyun Cheng · 1 shared paper, 2026 · strength 0.32
  13. Zhe Yang · 1 shared paper, 2024 · strength 0.26
  14. Ziyu Liang · 1 shared paper, 2022 · strength 0.19
  15. Zhe Yang · 1 shared paper, 2023 · strength 0.17
  16. Qiulan Huang · 2 shared papers, 2017 · strength 0.17
  17. Shi XY · 1 shared paper, 2022 · strength 0.16
  18. Qinglin He · 1 shared paper, 2020 · strength 0.16
  19. Dongcheng Lu · 1 shared paper, 2019 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.